CO2021003713A2 - Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors - Google Patents

Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors

Info

Publication number
CO2021003713A2
CO2021003713A2 CONC2021/0003713A CO2021003713A CO2021003713A2 CO 2021003713 A2 CO2021003713 A2 CO 2021003713A2 CO 2021003713 A CO2021003713 A CO 2021003713A CO 2021003713 A2 CO2021003713 A2 CO 2021003713A2
Authority
CO
Colombia
Prior art keywords
methods
disease
aging
compositions
treating
Prior art date
Application number
CONC2021/0003713A
Other languages
Spanish (es)
Inventor
Steven P Braithwaite
S Sakura Minami
Karoly Nikolich
Sanket V Rege
Arnaud E J Teichert
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CO2021003713A2 publication Critical patent/CO2021003713A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente invención se refiere a método para mejorar enfermedades neurodegenerativas con agentes moduladores de CCR3. Los métodos incluyen administrar una cantidad terapéuticamente efectiva del agente modulador de CCR3 al sujeto, con una mejora concomitante en la función cognitiva, motora u otra función afectada de manera neurodegenerativa. Las enfermedades cognitivas y motoras en las que los métodos de la invención pueden mejorar la cognición incluyen la enfermedad de Alzheimer, enfermedad de Parkinson, demencia frontotemporal, enfermedad de Huntington, esclerosis lateral amiotrófica, esclerosis múltiple, glaucoma, distrofia miotónica, demencia vascular, parálisis supranuclear progresiva.The present invention relates to a method for ameliorating neurodegenerative diseases with CCR3 modulating agents. The methods include administering a therapeutically effective amount of the CCR3 modulating agent to the subject, with a concomitant improvement in cognitive, motor, or other neurodegeneratively impaired function. Cognitive and motor diseases in which the methods of the invention can improve cognition include Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, glaucoma, myotonic dystrophy, vascular dementia, paralysis. progressive supranuclear.

CONC2021/0003713A 2018-09-26 2021-03-24 Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors CO2021003713A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26
PCT/US2019/052995 WO2020069008A1 (en) 2018-09-26 2019-09-25 Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Publications (1)

Publication Number Publication Date
CO2021003713A2 true CO2021003713A2 (en) 2021-04-08

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0003713A CO2021003713A2 (en) 2018-09-26 2021-03-24 Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors

Country Status (16)

Country Link
EP (1) EP3856195A4 (en)
JP (1) JP2022502441A (en)
KR (1) KR20210065950A (en)
CN (1) CN112789044A (en)
AU (1) AU2019346456A1 (en)
BR (1) BR112021004938A2 (en)
CA (1) CA3111433A1 (en)
CL (1) CL2021000724A1 (en)
CO (1) CO2021003713A2 (en)
EA (1) EA202190463A1 (en)
IL (1) IL281578A (en)
MA (1) MA53743A (en)
MX (1) MX2021002967A (en)
SG (1) SG11202102105VA (en)
TW (1) TW202027752A (en)
WO (1) WO2020069008A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (en) * 2010-10-07 2015-08-10 Common Crystals and Salts of CCR3 Inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
IL269743B (en) * 2017-04-05 2022-09-01 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) * 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors

Also Published As

Publication number Publication date
JP2022502441A (en) 2022-01-11
CA3111433A1 (en) 2020-04-02
CN112789044A (en) 2021-05-11
EA202190463A1 (en) 2021-06-29
KR20210065950A (en) 2021-06-04
MX2021002967A (en) 2021-08-11
BR112021004938A2 (en) 2021-06-01
SG11202102105VA (en) 2021-04-29
TW202027752A (en) 2020-08-01
IL281578A (en) 2021-05-31
MA53743A (en) 2022-01-05
EP3856195A1 (en) 2021-08-04
AU2019346456A1 (en) 2021-04-15
EP3856195A4 (en) 2022-06-22
WO2020069008A1 (en) 2020-04-02
CL2021000724A1 (en) 2021-10-15

Similar Documents

Publication Publication Date Title
CO2019012164A2 (en) Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors
MX2022004102A (en) Oligonucleotide compositions and methods of use thereof.
MX2019007586A (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases.
BR112018069533A2 (en) treatment of cyclodextrin eye allergic conditions
DOP2017000118A (en) 2-Amino-3,5-difluoro-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
BR112018074185A2 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
CO2017004465A2 (en) 2-amino-6- (difluoromethyl) -5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
BR112017026739A2 (en) compounds for use in the treatment of neuromuscular disorders
CL2019001891A1 (en) Bicyclic bis-heteroaryl derivatives as protein aggregation modulators.
TN2018000322A1 (en) Allosteric modulators of nicotinic acetylcholine receptors
CO2020003932A2 (en) Heterocyclic compound
BR112016006926A2 (en) compositions comprising a quinic acid-caffeic acid conjugate, therapeutic and cosmetic uses
MX357635B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism.
ECSP20042640A (en) DERIVATIVES OF INDOL 1, 3, 4, 5-TETRAHIDRO-2H-PIRIDO [4,3-B] FOR THE TREATMENT, RELIEF, OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES, SUCH AS ALZHEIMER'S DISEASE
BR112018013084A2 (en) combination treatments comprising administration of imidazopyrazinones
CL2019001752A1 (en) Bis-heteroaryl derivatives as modulators of protein aggregation.
CL2020000070A1 (en) Agents, uses and methods for treatment.
WO2020058979A3 (en) Methods of treating amyotrophic lateral sclerosis
BR112018069712A2 (en) compound or a pharmaceutically acceptable salt thereof, pharmaceutical composition, method for administering an effective amount of a pharmaceutical composition, and tnf-a inhibitor.
BR112017016378A2 (en) monomethyl fumarate prodrug compositions
CO2021003713A2 (en) Methods and compositions for treating deteriorations associated with aging using ccr3 inhibitors
WO2020117031A3 (en) Composition and method for inhibiting amyloid beta accumulation and/or aggregation
PE20220384A1 (en) COMPOSITIONS AND METHODS OF OXYMETAZOLINE FOR THE TREATMENT OF OCULAR DISORDERS
EA201890769A1 (en) 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES
JP1724082S (en) safety glasses